Patents by Inventor John Kanis

John Kanis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Androgen derivatives and uses thereof
    Patent number: 6916791
    Abstract: Androgen glycosides provide free, circulatory androgen on oral administration as they are subject to less, first pass breakdown by the liver.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: July 12, 2005
    Assignee: Strakan Limited
    Inventors: Michael F. Holick, John Kanis
  • Androgen derivatives and uses thereof
    Publication number: 20030216328
    Abstract: Androgen glycosides provide free, circulatory androgen on oral administration as they are subject to less, first pass breakdown by the liver.
    Type: Application
    Filed: May 30, 2003
    Publication date: November 20, 2003
    Applicant: Strakan Limited, a Bermuda Corporation
    Inventors: Michael F. Holick, John Kanis
  • Androgen derivatives and uses thereof
    Patent number: 6630453
    Abstract: Androgen glycosides provide free, circulatory androgen on oral administration as they are subject to less, first pass breakdown by the liver.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: October 7, 2003
    Assignee: Strakan Limited
    Inventors: Michael F. Holick, John Kanis
  • Combination of cholecalciferol derivatives for the treatment of renal bone disease
    Patent number: 4997824
    Abstract: A method and composition for an improved treatment of human renal osteodystrophy, comprising the administration of 6-40 mcg/d (micrograms per day) of 24,25(OH).sub.2 D.sub.3 in combination with amounts of 1-alpha(OH)D.sub. 3 or 1,25(OH).sub.2 D.sub.3 or DHT.sub.2, which will maintain in the serum of patients the calcium concentration at 10-11 mg/dl (milligrams per deciliter) and the phosphate concentration at 5.5-6.0 mg/dl (milligrams per deciliter) and the numerical multiplication product of calcium x phosphate not more than 60-65.
    Type: Grant
    Filed: July 22, 1987
    Date of Patent: March 5, 1991
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Mordecai Popovtzer, Ben Z. Weiner, Shmuel Edelstein, Zeev Mazor, David Ladkani, Benjamin Shalita, John A. Kanis